Lv4
608 积分 2024-03-04 加入
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China
2天前
已完结
Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2- Early Breast Cancer in China
10天前
已完结
Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
23天前
已关闭
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
27天前
已完结
Time-varying pattern of recurrence risk for Chinese breast cancer patients
1个月前
已完结
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression
1个月前
已完结
POSITIVE Results for Breast Cancer Survivors Who Desire Pregnancy
1个月前
已完结
皖公网安备34019202002308
